Of the mRNA front-runners, it was Moderna that most needed help. It was a leader in research, but it had only 800 employees and had never run a Phase III clinical trial. The managerial assistance Moderna received from Warp Speed was as important as the $2.5 billion in funding from the U.S. government.
